Table 1

Maternal characteristics of the study populations according to asthma treatment and asthma severity

		Asthma treatment			Asthma severity
	Control	No treatment	Inhaled corticosteroids	p Value	Mild	Moderate–severe	p Value
n	51	52	71		58	65
Age	29.8 (27.4 to 30.9)^*	25.7 (23 to 27)	26.7 (25 to 28)	<0.001	26.0 (23.4 to 26.8)	26.5 (25.0 to 28.0)	<0.001
Height (cm)	164.2 (162.2 to 165.9)	164.1 (161.8 to 166.1)	164.0 (162.7 to 165.8)	0.99	163.4 (162.0 to 166.0)	164.4 (162.6 to 165.8)	0.81
Weight (early) (kg)	73.9 (65.0 to 77.4)	76.9 (69.2 to 81.1	75.3 (69.8 to 81.3)	0.80	77.4 (68.9 to 80.7)	74.7 (70.0 to 81.6)	0.67
Weight (late) (kg)	83.0 (76.6 to 87.9)	88.3 (81.7 to 92.9	85.4 (80.5 to 91.2)	0.47	88.1 (82.2 to 92.8)	85.3 (80.2 to 91.2)	0.47
BMI	27.4 (24 to 29)	28.3 (26 to 30)	27.7 (26 to 30)	0.82	28.3 (25 to 30)	27.7 (26 to 30)	0.82
Gravida (median, range)	2 (1–10)	2 (1–8)	2 (1–8)	0.11	2 (1–8)	2 (1–8)	0.020
Parity (median, range)	1 (0–6)^*	0 (0–4)	1 (0–6)	0.011	0 (0–4)	1 (0–6)	0.004
FEV₁	3.2 (3.0 to 3.4)	3.2 (3.0 to 3.3)	3.0 (2.9 to 3.2)	0.10	3.2 (3.0 to 3.4)	3.0 (2.8 to 3.2)^†	0.043
Vital capacity	3.9 (3.8 to 4.1)	3.8 (3.6 to 4.0)	3.8 (3.6 to 3.9)	0.70	3.8 (3.6 to 3.9)	3.8 (3.6 to 3.9)	0.71
GC dose, third trimester	0	0	1054.2 (890.7 to 1233.2)^‡	<0.001	234.5 (123.8 to 350.3)^§	928.0 (705.9 to 1117.5)^‡	<0.001
Smoking n (%)	3 (5.9%)	14 (26.9%)	20 (28.2%)	0.006	12 (20.7%)^§	22 (33.8%)^§	0.001

Significance values represent a comparison of each asthma treatment and the control group and of each asthma severity and the control group. Data represent mean (95% CI) unless indicated.
↵* Significantly higher than the asthma groups.
↵† Significantly lower than the mild group.
↵‡ Significantly higher than the control and no treatment groups.
↵§ Significantly higher than the control group.
BMI, body mass index; FEV₁, forced expiratory volume in 1 s; GC, glucocorticoid.